IceCure Medical Ltd. (NASDAQ: ICCM) specializes in minimally-invasive cryoablation technology for the local treatment of low-risk breast cancer. This innovative approach offers an alternative to traditional surgical methods by freezing tumors. The company is expanding its presence in the U.S. and internationally, particularly after receiving FDA marketing authorization for its ProSense cryoablation system.
On November 19, 2025, ICCM reported its earnings, revealing an EPS of -$0.056, which fell short of the estimated EPS of -$0.05. Despite this, the company exceeded revenue expectations, reporting $725,000 compared to the estimated $714,000. This indicates that while the company is not yet profitable, it is generating more revenue than anticipated.
The earnings call, hosted by Seeking Alpha, featured key figures such as CEO Eyal Shamir and CFO Ronen Tsimerman. Participants from EVC Group Inc. and Maxim Group LLC also joined the call. The discussion highlighted the growing demand for ICCM's ProSense systems, which is expected to accelerate in 2026, targeting a U.S. patient population of approximately 200,000.
ICCM's financial metrics provide insight into its market valuation and financial health. The company has a price-to-sales ratio of 17.31, indicating that investors are willing to pay $17.31 for every dollar of sales. Its enterprise value to sales ratio is 16.23, reflecting a similar valuation from an enterprise perspective. These figures suggest that investors have high expectations for ICCM's future growth.
The company's debt-to-equity ratio is 0.82, showing a moderate level of debt compared to its equity. This suggests that ICCM is managing its debt responsibly. Additionally, with a current ratio of 1.18, ICCM has a slightly higher level of current assets compared to its current liabilities, indicating a reasonable level of short-term financial health.
